Prostate Cancer News

Two Advances in Prostate Cancers You Might Not Know About (September 8, 2017)

Prostate cancer isn’t just about men, and it may be inherited. A recent study led by Peter Nelson, MD (Fred Hutchinson Cancer Research Center) has shown that 12% of advanced prostate cancers may be caused by 16 different heritable genes. That means... Continue Reading

Is Lynparza a Precision Cancer Medicine for Prostate Cancer? (July 12, 2017)

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza (olaparib) into a precision medicine for prostate cancer. Lynparza is a PARP inhibitor, a newer precision cancer medicine that blocks enzymes involved in repairing... Continue Reading

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival (June 7, 2017)

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median time until the cancer worsened, from 14.8 months... Continue Reading

Unique Gene Signature Predicts Potentially Lethal Prostate Cancers (February 23, 2017)

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of... Continue Reading

Different Treatment Options Appear Equally Effective in Early Prostate Cancer (October 3, 2016)

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10... Continue Reading

Midlife PSA Levels Correlate to Risk of Future Lethal Prostate Cancer (August 15, 2016)

A baseline prostate-specific antigen (PSA) level among men at midlife appears to be highly correlated with the risk of developing lethal prostate cancer within their lifetimes. These results were recently published in the Journal of Clinical Oncology. Prostate... Continue Reading

New Tool Helps Men Evaluate Watchful Waiting in Early Stage Prostate Cancer (August 10, 2016)

Over 90 percent of prostate cancers are detected at a curable stage, with men more likely to die of other diseases than from this cancer. Although patients with localized, low-risk prostate cancer have treatment options: active surveillance, also called... Continue Reading

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (July 26, 2016)

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer... Continue Reading

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer (June 13, 2016)

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent prostate cancer. Prostate cancer is the second... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Latest Prostate Cancer News By Stage


Early Stage I-II (A-B) Prostate Cancer

Different Treatment Options Appear Equally Effective in Early Prostate Cancer (October 3, 2016)

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10... Continue Reading

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer (April 25, 2016)

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Shorter Course of Radiation as Effective as Longer Course in Low-Risk Prostate Cancer (November 5, 2015)

A shorter course of hypofractionated radiation therapy, a treatment in which larger doses of radiation are delivered over a shorter time period than conventional radiation, appears as effective as longer courses for men with low-risk prostate cancer.... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (August 17, 2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical... Continue Reading

More Early Stage I-II (A-B) Prostate Cancer

Locally Advanced Stage III (C) Prostate Cancer

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Gene-Targeted Drug Can Treat Prostate Cancer (October 29, 2015)

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib,... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (August 17, 2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical... Continue Reading

Radiation Plus Androgen-Deprivation Therapy Prolongs Survival for Older Men With Prostate Cancer (January 20, 2015)

According to the results of a study recently published in the Journal of Clinical Oncology, the addition of radiation treatment to treatment with androgen-deprivation therapy (ADT) in older men with locally advanced prostate therapy prolongs survival... Continue Reading

Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations (December 10, 2014)

CancerConnect News: Genomic Health, Inc. today announced results from two studies of the Oncotype DX® prostate cancer test demonstrating its value in low- and intermediate-risk prostate cancer to enable physicians and patients to avoid over- and under-treatment... Continue Reading

More Locally Advanced Stage III (C) Prostate Cancer

Metastatic Stage IV (D) Prostate Cancer

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (July 26, 2016)

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Gene-Targeted Drug Can Treat Prostate Cancer (October 29, 2015)

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib,... Continue Reading

Prostvac® Vaccine Promising in Treatment of Metastatic Castration-Resistant Prostate Cancer (June 1, 2015)

The prostate cancer vaccine Prostvac® (rilimogene galvacirepvec/rilimogene glafolivec) may be active in combination with Yervoy® (ipilimumab) in the treatment of metastatic prostate cancer that does not respond to hormone therapy. These findings were... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (February 23, 2015)

The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported in The Lancet Oncology... Continue Reading

More Metastatic Stage IV (D) Prostate Cancer

Refactory/Recurrent Prostate Cancer

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer (June 13, 2016)

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent prostate cancer. Prostate cancer is the second... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy (November 4, 2015)

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment for early prostate cancer often includes the surgical... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (February 23, 2015)

The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported in The Lancet Oncology... Continue Reading

Xofigo Extends Survival in Hormone-Refractory Prostate Cancer (November 6, 2014)

For patients with advanced hormone-refractory prostate cancer, the agent Xofigo® (radium-223) appears similarly effective in patients who have and have not received Taxotere® (docetaxel), a chemotherapy drug that can be used in the treatment of advanced... Continue Reading

More Refactory/Recurrent Prostate Cancer

Screening/Prevention Prostate Cancer

Midlife PSA Levels Correlate to Risk of Future Lethal Prostate Cancer (August 15, 2016)

A baseline prostate-specific antigen (PSA) level among men at midlife appears to be highly correlated with the risk of developing lethal prostate cancer within their lifetimes. These results were recently published in the Journal of Clinical Oncology. Prostate... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Fish Consumption Linked with Reduced Prostate Cancer Mortality (October 18, 2010)

A combined analysis of previous studies suggests that a diet high in fish may be linked with a reduction in risk of death from prostate cancer. These findings were recently published in the American Journal of Clinical Nutrition.[1] Other than skin cancer,... Continue Reading

Study Evaluates PSA Levels to Help Determine Which Men Will Benefit from Additional Prostate Cancer Screening and Treatment (September 23, 2010)

A large study demonstrates that a man’s baseline prostate specific antigen (PSA) level may help predict which men would benefit most from additional screening and treatment. These findings were recently published in the journal Cancer.[1] Men 50 years... Continue Reading

Brothers of Prostate Cancer Patients Undergo More Diagnostic Testing (September 7, 2010)

Some of the elevated risk of prostate cancer among those with a family history of the disease may be due to increased prostate cancer testing and detection in this population. These findings were recently published in the Journal of the National Cancer... Continue Reading

More Screening/Prevention Prostate Cancer